
## Michael A Rosenberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5606008/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Assessment of a Mobile Health iPhone App for Semiautomated Self-management of Chronic Recurrent Medical Conditions Using an N-of-1 Trial Framework: Feasibility Pilot Study. JMIR Formative Research, 2022, 6, e34827.	1.4	2
2	Qualitative Evaluation of an Artificial Intelligence–Based Clinical Decision Support System to Guide Rhythm Management of Atrial Fibrillation: Survey Study. JMIR Formative Research, 2022, 6, e36443.	1.4	1
3	Use of cell phone adapters is associated with reduction in disparities in remote monitoring of cardiac implantable electronic devices. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 469-475.	1.3	7
4	Feasibility of Frailty Assessment Integrated with Cardiac Implantable Electronic Device Clinic Follow-up: A Pilot Investigation. Gerontology and Geriatric Medicine, 2021, 7, 233372142098734.	1.5	1
5	Trusting Magic. Circulation, 2021, 143, 1299-1301.	1.6	10
6	Prediction of Drug-Induced Long QT Syndrome Using Machine Learning Applied to Harmonized Electronic Health Record Data. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 335-340.	2.0	13
7	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. JMIR Medical Informatics, 2021, 9, e29225.	2.6	5
8	Assessing Prescriber Behavior with a Clinical Decision Support Tool to Prevent Drug-Induced Long QT Syndrome. Applied Clinical Informatics, 2021, 12, 190-197.	1.7	5
9	Multicenter Analysis of Dosing Protocols for Sotalol Initiation. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 212-218.	2.0	9
10	Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data. BMC Medical Informatics and Decision Making, 2020, 20, 252.	3.0	13
11	Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. JAMA Network Open, 2020, 3, e1919396.	5.9	76
12	Frailty, Implantable Cardioverter Defibrillators, and Mortality: a Systematic Review. Journal of General Internal Medicine, 2019, 34, 2224-2231.	2.6	15
13	Follow-Up After CatheterÂAblation of Papillary Muscles and Valve Cusps. JACC: Clinical Electrophysiology, 2019, 5, 1185-1196.	3.2	8
14	Esophageal position, measured luminal temperatures, and risk of atrioesophageal fistula with atrial fibrillation ablation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 458-463.	1.2	6
15	Applications of machine learning in decision analysis for dose management for dofetilide. PLoS ONE, 2019, 14, e0227324.	2.5	25
16	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0
17	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		0
18	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14,		0

e0227324.

2

MICHAEL A ROSENBERG

#	Article	IF	CITATIONS
19	Applications of machine learning in decision analysis for dose management for dofetilide. , 2019, 14, e0227324.		Ο
20	Serum androgens and risk of atrial fibrillation in older men: The Cardiovascular Health Study. Clinical Cardiology, 2018, 41, 830-836.	1.8	18
21	Device-measured physical activity data for classification of patients with ventricular arrhythmia events: A pilot investigation. PLoS ONE, 2018, 13, e0206153.	2.5	10
22	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
23	Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk. Circulation, 2017, 135, 1300-1310.	1.6	96
24	Taller height as a risk factor for venous thromboembolism: a Mendelian randomization metaâ€analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1334-1343.	3.8	19
25	Validation of Polygenic Scores for QT Interval in Clinical Populations. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
26	Interlead heterogeneity of R―and Tâ€wave morphology in standard 12â€lead ECGs predicts sustained ventricular tachycardia/fibrillation and arrhythmic death in patients with cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2017, 28, 1324-1333.	1.7	19
27	Measures of Body Size and Composition and Risk of Incident Atrial Fibrillation in Older People. American Journal of Epidemiology, 2016, 183, 998-1007.	3.4	35
28	Left ventricular sphericity independently predicts appropriate implantable cardioverter-defibrillator therapy. Heart Rhythm, 2016, 13, 490-497.	0.7	30
29	Disease Focused Approach on Fibrosis Biomarkers in Cardiovascular Health. , 2016, , 601-634.		0
30	Disease Focused Approach on Fibrosis Biomarkers in Cardiovascular Health. , 2016, , 1-34.		0
31	Prevalence and Outcomes of Patients Receiving Implantable Cardioverter-Defibrillators for Primary Prevention Not Based on Guidelines. American Journal of Cardiology, 2015, 115, 1539-1544.	1.6	1
32	Circulating Fibrosis Biomarkers and Cardiovascular Health: Disease-Focused Approach in Heart Failure, Arrhythmias, Sudden Cardiac Death, and Atrial Fibrillation. , 2015, , 1-34.		0
33	Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). American Heart Journal, 2014, 167, 723-728.e2.	2.7	33
34	<scp>SIRT</scp> 2 induces the checkpoint kinase BubR1 to increase lifespan. EMBO Journal, 2014, 33, 1438-1453.	7.8	195
35	B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm, 2014, 11, 1109-1116.	0.7	70
36	Genetic Variants Related to Height and Risk of Atrial Fibrillation. American Journal of Epidemiology, 2014, 180, 215-222.	3.4	24

MICHAEL A ROSENBERG

#	Article	IF	CITATIONS
37	Height and risk of sudden cardiac death: the Atherosclerosis Risk in Communities and Cardiovascular Health Studies. Annals of Epidemiology, 2014, 24, 174-179.e2.	1.9	16
38	To the Editor—Spontaneous conversion of a long RP to short RP tachycardia: what is the mechanism?. Heart Rhythm, 2014, 11, E5.	0.7	0
39	Use of a Noninvasive Continuous Monitoring Device in the Management of Atrial Fibrillation: A Pilot Study. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 328-333.	1.2	145
40	Lowering the Risk for Thrombus and Stroke in Atrial Fibrillation Patients: Will Dabigatran Replace Warfarin?. Clinical Medicine Reviews in Vascular Health, 2013, 5, 1-8.	3.0	0
41	Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling. Circulation, 2012, 126, 2208-2219.	1.6	91
42	Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. European Heart Journal, 2012, 33, 904-912.	2.2	114
43	Diastolic Dysfunction and Risk of Atrial Fibrillation. Circulation, 2012, 126, 2353-2362.	1.6	156
44	The impact of height on the risk of atrial fibrillation: the Cardiovascular Health Study. European Heart Journal, 2012, 33, 2709-2717.	2.2	89
45	A Novel Transgenic Mouse Model of Cardiac Hypertrophy and Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 415.	0.5	17
46	The Estimated Risk of Atrial Fibrillation Related to Alcohol Consumption. Journal of Atrial Fibrillation, 2012, 5, 424.	0.5	4
47	The Nuclear Receptor Corepressor (NCoR) Controls Thyroid Hormone Sensitivity and the Set Point of the Hypothalamic-Pituitary-Thyroid Axis. Molecular Endocrinology, 2011, 25, 212-224.	3.7	73
48	mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. American Journal of Physiology - Cell Physiology, 2010, 299, C1256-C1266.	4.6	118
49	Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. American Journal of Physiology - Cell Physiology, 2009, 297, 1124-1132.	4.6	168
50	Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2009, 104, 128-132.	1.6	89
51	Effects of myostatin deletion in aging mice. Aging Cell, 2009, 8, 573-583.	6.7	96